Valneva's Stock Rebounds by 2.5%, Marking One of the Strongest Gains in the SBF 120
The Lyon-based biotech specializing in vaccines marks one of the sharpest rebounds in the index this Monday, in an overall well-oriented Parisian market. The stock is recovering after several challenging weeks, while still trading below all its moving averages.
A Session Rebound That Places the Stock Among the Strongest Gains in the SBF 120
Valneva's stock gains 2.62% at €2.236 in session, placing it among the strongest gains in the SBF 120, while the broader index only advances by 0.14%. The rebound comes after a difficult phase: the stock is still down 4.3% over the past week and nearly 16.4% over three months. The CAC 40, on the other hand, gains 0.13% at 8,349.67 points, in a market environment marked by Brent crude rising beyond $79 following a new escalation around the Strait of Hormuz. The movement of the day occurs a few sessions after a low point reached on July 7, when the stock came back to the support at €2.21, tested for the first time at the end of June. This threshold is holding for now. The biotech remains far from its highs: the stock loses more than 38% compared to its 200-day moving average at €3.64.
Stock Still Below Its Three Moving Averages Despite Today's Recovery
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The technical setup remains unfavorable. The price at €2.236 is below the MM20 (€2.37, a gap of -5.65%) and the MM50 (€2.44, a gap of -8.36%). Today's rebound brings the stock close to its short-term moving average, without yet crossing it. The RSI at 43 remains in a neutral zone, indicating a lack of dominant buying or selling pressure at this stage. On the fundamentals, the company adjusted its trajectory during the first quarter 2026 announcement on May 13, targeting an annual revenue between €135 million and €150 million. This revision, combined with the decline in third-party product sales mentioned in the group's risks, has weighed on the biotech's stock trajectory for several months. The support at €2.21 remains the short-term technical reference level, with the next resistance at €2.67.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 65,8 millions d'euros
Quarterly revenue: 65,8 millions d'euros
Revenue growth: -32,6 %
EBITDA: -39,8 millions d'euros
Net income: -63,3 millions d'euros
Guidance from the release
Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
Expected revenue: 147,5 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.